LIVE Programme CEST time

Translational Research E- Conference
ACUTE LYMPHOBLASTIC LEUKAEMIA

May 7-9, 2021

Chairpersons: Jan Cools (Leuven), Hervé Dombret (Paris), Adele Fielding (London), Mark Litzow (Rochester)

Friday, May 7th, 2021

13:50-14:00 Welcome : The 4 Chairpersons

SESSION I – BIOLOGY OF B-CELL PRECURSOR ALL
Chairs: Jan Cools (Leuven) & Adolfo Ferrando (New York)

14:00-14:05	Introduction	Jan Cools & Adolfo Ferrando
14:05-14:25	Keynote: HOX Gene Deregulation in ALL	Scott Armstrong (Boston)
14:25-14:40	Transcriptional Landscape of B-cell Precursor ALL	Henrik Lilljebjörn (Lund)
14:40-14:55	Myeloid Switch of B-cell Precursor ALL Subtypes	Ester Mejstrikova (Prague)
14:55-15:10	Targeting Novel B-cell progenitor ALL Subtypes	Charles Mullighan (Memphis)

BRIEF ORAL COMMUNICATION:

15:10-15:20	*Mechanistic Basis for Targeting BCL6 in RAS-Driven B-Cell Acute Lymphoblastic Leukemia*	*Lai Chan (New Haven)*
15:20-15:50	*Panel discussion*	

SESSION II – BIOLOGY OF T-CELL ALL
Chairs: Charles Mullighan (Memphis) & Scott Armstrong (Boston)

15:50-15:55	Introduction	Charles Mullighan & Scott Armstrong
15:55-16:10	Molecular Mechanisms of T-ALL	Adolfo Ferrando (New York)
16:10-16:25	Aberrant Signaling in T-cell ALL	Jan Cools (Leuven)
16:25-16:40	Targeting CD3 in T-ALL	Jacques Ghysdael (Orsay)

LIVE Programme CEST time

BRIEF ORAL COMMUNICATION:

16:40-16:50	*Tonic T-Cell Receptor Signaling Is Leukemogenic While Its Antigenic Stimulation Suppresses Leukemia Development*	*Telmo A. Catarino (Porto)*
16:50-17:20	*Panel discussion*	
17:20-17:30	***Break***	

SESSION III – MINIMAL RESIDUAL DISEASE MONITORING
Chairs: Sabina Chiaretti (Rome) & Selina Luger (Philadelphia)

17:30-17:35	Introduction	Sabina Chiaretti & Selina Luger
17:35-17:50	Euro MRD Activities	Beat Schäfer (Zurich)
17:50-18:05	Which MRD for ALL Treatment Stratification?	Monika Brüggemann (Kiel)
18:05-18:20	IG-TCR *versus* BCR-ABL1 MRD in Ph+ ALL	Jan Zuna (Prague)

BRIEF ORAL COMMUNICATION:

18:20-18:30	*Knockout of HMGN1 In Vivo reduces CRLF2r down Syndrome Acute Lymphoblastic Leukaemia Burden and Increases Survival Outcomes*	*Elyse Page (Adelaide)*
18:30-19:00	*Panel discussion*	
19:00	**Mentored Poster Walk #1** *Poster Leaders: Richard Burt (London) & Anna Castleton (Manchester)*	

Saturday, May 8th, 2021

10:30-11:30 **2 Simultaneous Meet the Expert sessions (non clinical)**
- Role of HSCT in Ph+ ALL: Oliver Ottmann & Hervé Dombret
- Monitoring L-asparaginase Efficacy in ALL Patients: Mathilde Hunault & Adele Fielding

11:30-12:30 **Mentored Poster Walk #2**
Poster Leaders: Bela Wrench (London) & Charles de Bock (Sydney)

12:30-13:30 **Lunch**

SESSION IV – INDIVIDUALIZED MANAGEMENT OF ALL
Chairs: Nicola Gökbuget (Frankfurt) & Elizabeth Raetz (New York)

13:30-13:35	Introduction	Nicola Gökbuget & Elizabetch Raetz
13:35-13:50	Treatment Issues in Teenagers and Young Adults ALL	Rachael Hough (London)

LIVE Programme CEST time

13:50-14:05	Treatment Issues in Older ALL	Selina Luger (Philadelphia)
14:05-14:20	Management of Relapsed ALL	Elias Jabbour (Houston)

BRIEF ORAL COMMUNICATION:

14:20-14:30	*T(1;19)(q23;p13) TCF3-PBX1 May Not be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated with MRD-Oriented Protocols from the Pethema Group*	*Jordi Ribera (Badalona)*
14:30-15:00	*Panel discussion*	

SESSION V – NEW ADVANCES IN ALL
Chairs: Hervé Dombret (Paris) & Shannon Maude (Philadelphia)

15:00-15:05	Introduction	Hervé Dombret & Shannon Maude
15:05-15:20	The Critical Role of Microenvironment in ALL	Adele Fielding (London)
15:20-15:35	TKI Use in Ph+/Ph-like Diseases	Stephen Hunger (Philadelphia)
15:35-15:50	New ALL Drugs	Matthew Wieduwilt (San Diego)

BRIEF ORAL COMMUNICATIONS:

15:50-16:00	*Lysosome-Mediated Dysregulation of Lipid Metabolism Selectively Induces Autophagy-Dependent Cell Death in T-ALL*	*Ruth M Risueño (Barcelona)*
16:00-16:10	*Pharmacologic Inhibition of DYRK1A Results in Hyperphosphorylation of ERK and Consequently in Apoptosis of KMT2A-Rearranged ALL*	*Christian Hurtz (Philadelphia)*
16:10-16:20	*Oncogenic Cooperation between the TCF7-SPI1 fusion and NRAS(G12D) Requires β-Catenin Activity to Drive T-Cell Acute Lymphoblastic Leukemia.*	*Quentin Van Thillo (Leuven)*
16:20-16:50	*Panel discussion*	

16:50-17:00 Break

SESSION VI – CAR T-CELLS & ALLOGENEIC HSCT
Chairs: Adele Fielding (London) & Nicolas Boissel (Paris)

17:00-17:05	Introduction	Adele Fielding & Nicolas Boissel
17:05-17:20	Outcome of ALL Patients Treated with CAR T-cells	Shannon Maude (Philadelphia)
17:20-17:35	New CARs for B-cell Precursor ALL	Claire Roddie (London)
17:35-17:50	Post-transplant Interventions	David Marks (Bristol)
17:50-18:20	*Panel discussion*	

LIVE Programme CEST time

SESSION VII – FRONTLINE INCORPORATION OF BiTEs and ADCs
Chairs: Mark Litzow (Rochester) & Anjali Advani (Cleveland)

18:20-18:25	Introduction	Mark Litzow & Anjali Advani
18:25-18:45	Keynote: The MD Anderson Cancer Center Experience	Hagop Kantarjian (Houston)
18:45-19:00	Adult ALL Trials	Nicola Gökbuget (Frankfurt)
19:00-19:15	Childhood ALL Trials	Lia Gore (Aurora)
19:15-19:30	Frontline Chemo-free Regimens in Ph+ ALL	Sabina Chiaretti (Rome)
19:30-20:00	*Panel discussion*	

Sunday, May 9th, 2021

13:00-14:00 **4 Simultaneous Meet the Expert Sessions (Non- Clinical & Clinical)**
- **CAR T-cells : Practical Issues:** Nicolas Boissel & Shannon Maude
- **MRD Issues:** Monika Brüggemann & Jan Zuna
- **Allogenic SCT in ALL: Open issues:** David Marks & Mark Litzow
- **Optimal use if BiTEs:** Nicola Gökbuget & Matthew Wieduwilt

SESSION VIII – T-CELL ALL and LYMPHOBLASTIC LYMPHOMA
Chairs: Anjali Advani (Cleveland) & David Marks (Bristol)

14:00-14:05	Introduction	Anjali Advani & David Marks
14:05-14:25	Keynote: Management of T-LL Patients	Dieter Hoelzer (Frankfurt)
14:25-14:40	Risk Factors in T-ALL	Elizabeth Raetz (New York)
14:40-14:55	Should T-LL and T-ALLs be treated on the same protocols?	Elisabeth Macintyre (Paris)
14:55-15:10	Novel Therapies for T-ALL/LL	Anjali Advani (Cleveland)

BRIEF ORAL COMMUNICATION:

15:10-15:20	*Pre-T Cell Receptor As a Therapeutic Target in T-Cell Acute Lymphoblastic Leukemia*	*Maria L Toribio (Madrid)*
15:20-15:50	*Panel discussion*	
15:50-16:00	***Break***	

SESSION IX – Ph AND Ph-LIKE ALL
Chairs: Oliver Ottmann (Cardiff) & Sabina Chiaretti (Rome)

16:00-16:05	Introduction	Oliver Ottmann & Sabina Chiaretti

LIVE Programme CEST time

16:05-16:20	Which TKI-Chemo-Transplant Cocktail for Ph+ ALL?	Yves Chalandon (Geneva)
16:20-16:35	Next generation TKIs for Ph+ ALL	Nicholas Short (Houston)
16:35-16:50	Ph-like ALL Patient Management	Sarah Tasian (Philadelphia)

BRIEF ORAL COMMUNICATION:

16:50-17:00	*IL7R Gain-of-Function Mutation Is Sufficient to Initiate B-Cell Acute Lymphoblastic Leukemia In Vivo with Features of PAX5 P80R and Ph-like ALL*	*Afonso R.M. Almeida (Lisboa)*
17:00-17:30	*Panel discussion*	

17:30-17:45 Closing Remarks: The 4 Chairpersons